ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

AGC eyes Japanese output of mRNA to spur domestic COVID vaccines

Materials maker to invest in Yokohama plant, preparing for pandemics

AGC, which operates this site in Italy, hopes to boost production capabilities at its plants in Japan. 

TOKYO -- Japanese materials maker AGC aims to begin domestic production of messenger RNA, used in manufacturing COVID-19 vaccines, as early as 2025, Nikkei has learned.

The company plans to supply the ingredient to Japanese pharmaceutical firms such as Daiichi Sankyo that are developing locally produced vaccines. Japan is pushing for domestic development and manufacturing of vaccines as crucial to economic security, and this effort includes mass production of core materials such as mRNA.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more